Men at highest risk for prostate cancermay be rapidly investigated if genetic risk is considered in general practice. New research suggests.
Scientist examined the impact of incorporating genetic risk for cancer into her GP's triage and referral process.
This study concludes that considering genetic risk can improve referrals to those in need and avoid invasive biopsies in people at low cancer risk. I was.
They suggest that genetic risk assessment in primary care may lead to early diagnosis of men at highest risk of prostate cancer.
14} Prostate cancer accounts for about a quarter of new cancer cases in men, with 52,000 diagnosed annually in the UK.It is the second leading cause of cancer death in men in the UK, and if diagnosed early, has twice as many five-year survival rates as his.
Not only can high-risk patients
Principal Investigator Dr Sarah Bailey
Symptoms are common and easily misdiagnosed. they were previously diagnosed.
According to scholars from the University of Exeter, GPs make about 800,000 suspected prostate cancer referrals in the UK each year, with genetic Incorporating risk could potentially treat about 160,000 men quickly. Investigate faster.
They said genetic risk considerations could save 320,000 referrals and men undergoing unpleasant surveys.
First author Dr. Harry Green said:
The prostate-specific antigen test is currently used to investigate men with erectile dysfunction or dysuria, but the accuracy of the test is unknown and false-positive results are common.
Only one in three men with a positive antigen test will have cancer, and diagnosis often requires an invasive and uncomfortable biopsy.
The team used more than 250 known prostate cancer-associated genetic variants to calculate the genetic risk of prostate cancer.
Our study adds genetic risk to the risk assessment of patient symptoms by GPs.
Lead author Harry Greene, Ph.D.
These genetic variants are combined into a single 'genetic risk score'. It represents an individual's genetic risk of developing prostate cancer.
They applied this to his data of 6,390 Caucasian European men in the UK Biobank.
Principal Investigator Dr. Sarah Bailey said:
"Not only can high-risk patients be followed quickly, but low-risk patients can safely avoid invasive investigations.
"Using this technology It would fit well with the NHS long-term plan, which promises to be the first national health system to offer whole-genome sequencing as part of routine care.
"This will improve early diagnosis." , may serve as a clear example of improved treatment and survival."
The study was funded by Kirsten Higgins, whose family is a longtime supporter of the University of Exeter.
She said:
"It is very exciting to see the real benefits that this revolutionary new approach can bring to patients."
– Predicting Prostate Cancer Diagnosis A study applying prostate cancer genetic risk scores to men with lower urinary tract symptoms in primary 3 care: a UK Biobank cohort study published in the British Journal of. cancer.
